249 related articles for article (PubMed ID: 27389050)
1. Pharmacological aspects of the safety of gliflozins.
Faillie JL
Pharmacol Res; 2017 Apr; 118():71-81. PubMed ID: 27389050
[TBL] [Abstract][Full Text] [Related]
2. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
4. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective.
Madaan T; Akhtar M; Najmi AK
Eur J Pharm Sci; 2016 Oct; 93():244-52. PubMed ID: 27531551
[TBL] [Abstract][Full Text] [Related]
5. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
[TBL] [Abstract][Full Text] [Related]
6. In brief: ketoacidosis with SGLT2 inhibitors.
Med Lett Drugs Ther; 2015 Jun; 57(1471):94. PubMed ID: 26079766
[No Abstract] [Full Text] [Related]
7. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Mar; 130(3):159-69. PubMed ID: 26970780
[TBL] [Abstract][Full Text] [Related]
8. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors: Benefit/Risk Balance.
Scheen AJ
Curr Diab Rep; 2016 Oct; 16(10):92. PubMed ID: 27541294
[TBL] [Abstract][Full Text] [Related]
10. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N
Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972
[TBL] [Abstract][Full Text] [Related]
11. Possible adverse effects of SGLT2 inhibitors on bone.
Taylor SI; Blau JE; Rother KI
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):8-10. PubMed ID: 25523498
[No Abstract] [Full Text] [Related]
12. [Empagliflozin in the elderly].
Berrut G; Boureau AS; Trochu JN; Genet B; de Decker L; Hanon O
Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun; 19(2):137-147. PubMed ID: 34165436
[TBL] [Abstract][Full Text] [Related]
13. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
14. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
15. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
16. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM
Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
19. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
Handelsman Y
Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
[No Abstract] [Full Text] [Related]
[Next] [New Search]
